Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 7/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3979698 | 1.00 | TACR2 (0.42) | TACR2USP2CYP3A4TSHRCYP1A2 | |
| SCHEMBL3979429 | 0.93 | RHOC (0.39) | TACR2USP2CYP3A4TSHRCYP1A2 | |
| SCHEMBL3979427 | 0.93 | RHOC (0.39) | TACR2USP2CYP3A4TSHRCYP1A2 | |
| SCHEMBL3985800 | 0.92 | TACR2 (0.36) | TACR2USP2CYP3A4TSHRCYP1A2 | |
| SCHEMBL3985802 | 0.92 | TACR2 (0.36) | TACR2USP2CYP3A4TSHRCYP1A2 | |
| SCHEMBL5106738 | 0.91 | TACR2 (0.38) | TACR2USP2CYP3A4TSHRCYP1A2 | |
| SCHEMBL4870849 | 0.91 | TACR2 (0.38) | TACR2USP2CYP3A4TSHRCYP1A2 | |
| SCHEMBL3980108 | 0.90 | ALDH1A1 (0.37) | TACR2USP2CYP3A4TSHRCYP1A2 | |
| SCHEMBL3984404 | 0.90 | ALDH1A1 (0.37) | TACR2USP2CYP3A4TSHRCYP1A2 | |
| SCHEMBL3987362 | 0.90 | CNR1 (0.39) | TACR2USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135434-A1 | Sulfonyloxy derivatives | SANKYO COMPANY, LIMITED (JP) | 2007-06-14 | — | — | US | claimed |
| EP-1754701-A1 | SULFONYLOXY DERIVATIVES | Sankyo Company, Limited (JP) | 2007-02-21 | — | — | EP | claimed |
| US-7560549-B2 | Sulfonyloxy derivatives | SANKYO COMPANY, LIMITED (JP) | 2009-07-14 | — | — | US | disclosed |
| US-20070135434-A1 | Sulfonyloxy derivatives | SANKYO COMPANY, LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1754701-A1 | SULFONYLOXY DERIVATIVES | Sankyo Company, Limited (JP) | 2007-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135434-A1 | Sulfonyloxy derivatives | TACR1, NPSR1, TACR2 | TACR2 3/4885USP2 4155/4885CYP3A4 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.